readthroughSign in
CompanySKYENasdaqSan Diego, CA

Skye Bioscience, Inc.

Skye Bioscience develops nimacimab, a negative allosteric modulating antibody that peripherally inhibits the CB1 receptor for weight loss in patients with obesity or overweight.

10-QNov 13Latest SEC filing
Nov 12Latest story